$16.12
3.47% yesterday
Nasdaq, Sep 04, 10:00 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$16.12
+0.03 0.19% 1M
-2.37 12.82% 6M
-8.65 34.92% YTD
-14.57 47.47% 1Y
+10.70 197.42% 3Y
-19.88 55.22% 5Y
+6.17 62.01% 10Y
+6.17 62.01% 20Y
Nasdaq, Closing price Thu, Sep 04 2025
-0.58 3.47%
ISIN
US45258J1025
Symbol
IMVT
Industry

Key metrics

Basic
Market capitalization
$2.9b
Enterprise Value
$2.3b
Net debt
positive
Cash
$598.9m
Shares outstanding
171.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.8
Financial Health
Equity Ratio
91.1%
Return on Equity
-58.5%
ROCE
-77.4%
ROIC
-882.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-470.7m | $-485.8m
EBIT
$-471.1m | $-546.6m
Net Income
$-447.3m | $-510.6m
Free Cash Flow
$-417.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-57.8% | -11.0%
EBIT
-57.8% | -24.7%
Net Income
-64.1% | -23.4%
Free Cash Flow
-71.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.6
FCF per Share
$-2.4
Short interest
26.9%
Employees
207
Rev per Employee
$0.0
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Immunovant Inc forecast:

17x Buy
77%
5x Hold
23%

Analyst Opinions

22 Analysts have issued a Immunovant Inc forecast:

Buy
77%
Hold
23%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 84 84
39% 39%
-
- Research and Development Expense 387 387
63% 63%
-
-471 -471
58% 58%
-
- Depreciation and Amortization 0.40 0.40
54% 54%
-
EBIT (Operating Income) EBIT -471 -471
58% 58%
-
Net Profit -447 -447
64% 64%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Positive
The Motley Fool
one day ago
Wednesday might have been a Hump Day of a slog to some investors, but not for those holding shares of Immunovant (IMVT 10.82%). On some rather encouraging news from the laboratory, the clinical-stage biotech's shares gained almost 11% in value, easily topping the 0.5% rise of the benchmark S&P 500 (^GSPC 0.51%).
Neutral
GlobeNewsWire
one day ago
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves' disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid A...
Neutral
GlobeNewsWire
25 days ago
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quarter ended June 30, 2025.
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Eric Venker
Employees 207
Founded 2018
Website immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today